Artificial intelligence is transforming life sciences and healthcare, yet regulation remains complex. On January 30, 2025, we joined industry leaders from pharma, MedTech, and digital health to explore the opportunities and challenges of the EU AI Act — through dynamic keynotes, panel discussions, and breakout sessions. Key takeaways included:
Artificial intelligence is transforming life sciences and healthcare, yet regulation remains complex. On January 30, 2025, we joined industry leaders from pharma, MedTech, and digital health to explore the opportunities and challenges of the EU AI Act — through dynamic keynotes, panel discussions, and breakout sessions. Key takeaways included:
- Unlocking innovation: AI is accelerating drug development, optimizing clinical trials, and enhancing patient care. The right governance structures are critical to implementing the AI Act while fostering innovation.
- Navigating complexity: Aligning the AI Act with existing frameworks like the Medical Device Regulation (MDR) and European pharmaceutical legislation requires a strategic, integrated approach.
- Adapting to change: AI is evolving fast, and regulation must keep up. Companies should build flexibility into their AI strategies to stay ahead of future developments.
AI regulation in life sciences remains an evolving landscape. We’ll continue tracking key developments and supporting you with actionable insights. Thank you to our lead partners Fabien Roy and Arne Thiermann, keynote speaker Jan Beger, and our speakers and panelists: Dr Joerg Schickert, Dr. Henning Düwert, LL.M., Dr. Pascal Hofer, Anisa Idris, Nicolaus Westerkamp, Matthias M. Schweiger, Joke Bodewits, Dr. Christian Tinnefeld, David Bamberg, Hannah Wiborg, and Martin Pflüger — along with everyone who joined us for these crucial discussions.